x

Posted 13 October, 2023

DocGo Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:DCGO in a 8-K filed on 13 October, 2023.


  As previously reported, Anthony Capone resigned as the Chief Executive Officer of DocGo Inc. (the "Company") effective September 15, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of DocGo Inc.
Health Care/Life Sciences • Healthcare Provision
DocGo, Inc. engages in the provision of mobile health services. It operates through the following segments: Transportation Services, Mobile Health Solutions, and Corporate. The Transportation Services segment offers on-demand medical mobility solutions which are marketed under the Ambulnz brand. The Mobile Health Solutions segment includes on-site evaluations, diagnostics, triage, treatment, and medicine administration. The Corporate segment consists of information technology expenses. The company was founded in 2015 by Stanley Vashovsky and is headquartered in New York, NY.
Market Cap
$378M
View Company Details
DocGo Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


As previously reported, Anthony Capone resigned as the Chief Executive Officer of DocGo Inc. (the "Company") effective September 15, 2023. On October 11, 2023, the Company and Mr. Capone entered into a separation and transition services agreement (the "Transition Agreement"). Pursuant to the Transition Agreement, Mr. Capone will continue to serve as a consultant to the Company until March 15, 2024 (such period, the "Consulting Period") to advise on matters relating to business continuity and processes and transition his institutional knowledge with respect to operational and other departmental functions.


As compensation for his services during the Consulting Period, and subject to his compliance with the Transition Agreement, including the execution and non-revocation of a general release of claims in favor of the Company, Mr. Capone will receive a monthly consulting fee of $45,000 and subsidized premiums for continued group health plan coverage for the duration of the Consulting Period. Mr. Capone will not receive new equity awards or incentive compensation under the Company's equity incentive compensation program during the Consulting Period. The Transition Agreement further acknowledges and affirms that Mr. Capone will be bound by and comply with certain restrictive covenants.


The foregoing description of the Transition Agreement does not purport to be complete and is qualified in its entirety by the full text of the Transition Agreement, a copy of which is filed herewith as Exhibit 10.1 and incorporated by reference herein.